C Cullen

Cindy Cullen

Senior Director, Business Development
  • Quality Measurement
  • Process Analysis
  • Requirements and Specifications Development
  • Quality Assurance
  • Testing
Focus Areas
  • Health
  • Medicaid and CHIP
  • Medicare
About Cindy
Cindy Cullen, associate director, is Mathematica’s measure development offering leader, serving as the product manager for clinical quality measures and the program manager of Mathematica’s current Measure & Instrument Development and Support II master contract. She has served as the project director for Mathematica’s Hospital Inpatient and Outpatient Process and Structural Measure Development and Maintenance project and the American Recovery and Reinvestment Act of 2009 Health Information Technology for Economic and Clinical Health Act Eligible Professional Clinical Quality Measures project. Both projects are large-scale measure development projects sponsored by the Centers for Medicare & Medicaid Services. She has been an invited attendee at several Lean Kaizen events sponsored by the Centers for Medicare & Medicaid Services, the Office of the National Coordinator for Health Information Technology, and the National Quality Forum to redesign processes and documents supporting measure development, maintenance, and endorsement. Cullen has experience in all phases of developing and implementing measures in various leadership roles. On these projects, she was responsible for budget, schedule, staffing and staff development, client interaction, subcontractor management, and quality. Her proven leadership of Mathematica staff, skill coordinating subcontractors and consultants, and dedication to team building and mentoring ensures overall program success and work quality. Cullen holds an M.S. in aerospace engineering from Texas A & M University and an M.B.A. from Oklahoma State University, and she is certified as a Project Management Professional.
Key Projects
Latest News
  • Graphic representing opioid misuse
    Mathematica Develops Safe Use of Opioids Measure

    As the nation continues to grapple with the opioid epidemic, numerous federal organizations are focusing on reducing unintentional drug overdoses. Emerging evidence shows that adverse drug events because of concurrent prescribing are a serious problem.